AERI - Aerie Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
24.02
-0.35 (-1.44%)
At close: 4:00PM EDT

23.95 -0.07 (-0.29%)
After hours: 6:34PM EDT

Stock chart is not supported by your current browser
Previous Close24.37
Open24.37
Bid21.11 x 1300
Ask24.04 x 800
Day's Range23.12 - 24.40
52 Week Range23.12 - 74.75
Volume664,808
Avg. Volume654,120
Market Cap1.103B
Beta (3Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-5.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est76.00
Trade prices are not sourced from all markets
  • How a Durham firm stands to benefit from an unexpected break in a Japanese trial
    American City Business Journals7 days ago

    How a Durham firm stands to benefit from an unexpected break in a Japanese trial

    Schedule changes in drug development are not uncommon, but one Triangle drug developer is facing an unusual situation: an unexpected stroke of luck that could shorten its drug development by several months.

  • Aerie Completes Enrollment Under Rhopressa Study in Japan
    Zacks9 days ago

    Aerie Completes Enrollment Under Rhopressa Study in Japan

    Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.

  • Business Wire9 days ago

    Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that enrollment for its Phase 2 clinical trial of netarsudil ophthalmic solution in Japan is complete, a milestone reached several months earlier than previously anticipated. In approximately 3 months, a total of 215 patients were successfully randomized across four treatment arms: netarsudil ophthalmic solution 0.01%, netarsudil ophthalmic solution 0.02%, netarsudil ophthalmic solution 0.04%, and placebo, all administered once daily in the evening. Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa® in the United States where it is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

  • Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
    Zacks24 days ago

    Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza

    Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.

  • Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy?
    Insider Monkey28 days ago

    Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy?

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged during the first quarter. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 40% and 25% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted […]

  • Markitlast month

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Aerie Pharmaceuticals Inc NASDAQ NMS:AERIView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding AERI are favorable, with net inflows of $2.36 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of AERI earnings conference call or presentation 7-May-19 9:00pm GMT

    Q1 2019 Aerie Pharmaceuticals Inc Earnings Call

  • Business Wirelast month

    Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Jeffrey Calabrese, CPA, as Director of Accounting, reporting to Christopher Staten, Aerie’s Vice President of Finance. Mr. Calabrese will lead external financial reporting, technical accounting and equity accounting. In connection with his acceptance of the position as Director of Accounting, Mr. Calabrese will receive awards totaling 14,400 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date.

  • Business Wirelast month

    Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences

    Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the trea

  • Does Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Have A Particularly Volatile Share Price?
    Simply Wall St.last month

    Does Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Have A Particularly Volatile Share Price?

    Anyone researching Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) might want to consider the historical volatility of the...

  • Why Is Aerie (AERI) Down 10.2% Since Last Earnings Report?
    Zackslast month

    Why Is Aerie (AERI) Down 10.2% Since Last Earnings Report?

    Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire2 months ago

    Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 2:30 p.m. Eastern Time in New York, NY. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye.

  • Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
    Zacks2 months ago

    Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint

    Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.

  • Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates
    Zacks2 months ago

    Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates

    Aerie (AERI) reports narrower-than-expected Q1 loss. However, Rhopressa lags expectations.

  • Aerie Pharmaceuticals, Inc. (AERI) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Aerie Pharmaceuticals, Inc. (AERI) Q1 2019 Earnings Call Transcript

    AERI earnings call for the period ending March 31, 2019.

  • Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates

    Aerie (AERI) delivered earnings and revenue surprises of 14.29% and -14.27%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Aerie: 1Q Earnings Snapshot

    The North Carolina, North Carolina-based company said it had a loss of $1.06 per share. Losses, adjusted for non-recurring costs, came to 78 cents per share. The results exceeded Wall Street expectations. ...

  • Business Wire2 months ago

    Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

    Conference Call and Webcast Today, May 7th, at 5:00 p.m. ET

  • Another $100 million 'safety net' set for this Triangle pharma
    American City Business Journals2 months ago

    Another $100 million 'safety net' set for this Triangle pharma

    Just days following the commercial launch of its second drug, Aerie Pharmaceuticals has negotiated another $100 million in credit.

  • Business Wire3 months ago

    Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it has entered into an amendment of its existing credit agreement with certain affiliates of Deerfield Management Company L.P. (Deerfield). The amendment provides for an additional $100 million senior secured delayed draw term loan facility (the additional credit facility), pursuant to which Aerie may borrow up to $100 million in aggregate in one or more borrowings at any time on or prior to July 23, 2020. Amounts drawn under the additional credit facility will amortize in equal annual installments beginning on July 20, 2023 and will mature on July 23, 2024.

  • Here’s What Hedge Funds Think About Aerie Pharmaceuticals Inc (AERI)
    Insider Monkey3 months ago

    Here’s What Hedge Funds Think About Aerie Pharmaceuticals Inc (AERI)

    It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]

  • With profits in sight, Durham pharma launches new trials
    American City Business Journals3 months ago

    With profits in sight, Durham pharma launches new trials

    In the midst of the commercial launch for its newest drug, one Durham pharmaceutical company is launching trials of another – though one with a considerably longer, self-funded runway.